Cooper Companies (COO) risk factors: FY2025 10-K

1. Current market conditions and recessionary pressures in one or more of our markets could impact our ability to grow our business.
2. Inflation could materially adversely affect our business.
3. Our substantial and expanding international operations are subject to uncertainties which could affect our business.
4. Economic and trade sanctions, including tariff and import/export regulations by the U.S. and foreign governments, could make it more difficult or costly for us to conduct our operations or achieve our business objectives.rewordedTariffs
5. Acquisitions and other strategic transactions that we have made and may make in the future involve numerous risks.
6. We face risks associated with disruption of our manufacturing, distribution and storage operations, including possible failure to develop necessary manufacturing processes, or constrained, idle or excess capacity, which could adversely affect our business.
7. Cybersecurity threats continue to increase in frequency and sophistication; a successful cybersecurity attack could interrupt or disrupt our information technology systems, or those of our third-party service providers, or cause the loss of confidential or protected data which could disrupt our business, force us to incur excessive costs or cause reputational harm.Cybersecurity
8. We manage our businesses utilizing multiple complex integrated software and hardware information technology operating systems that are regularly maintained and upgraded; an interruption or disruption to these systems could disrupt our business or force us to incur excessive costs.
9. We previously identified a material weakness in our internal control over financial reporting related to an ineffective information technology (IT) general control for the U.S. operations within the CooperSurgical segment which was remediated as of October 31, 2025. We may experience additional material weakness in the future which could affect our ability to record, process and report financial information accurately and prepare financial statements within required time periods and could subject us to litigation or investigations, negatively affect investor confidence and adversely impact our stock price.reworded
10. Pricing pressure from our competitors, customers and changes in third-party coverage and reimbursement may adversely affect demand for our products and negatively impact our operating results.
11. We rely on independent suppliers and third-party logistics providers in our supply chain for raw materials, packaging materials and components, mechanical equipment and some finished goods; we could experience inventory shortages if any of these suppliers encounter a manufacturing or distribution disruption.reworded
12. If we fail to protect our intellectual property adequately, our business could suffer.
13. Our products or processes could be subject to claims of infringement of the intellectual property of others.
14. We could experience losses from product liability claims or legal claims relating to our service offerings, including such claims and other losses resulting from sales of counterfeit and other infringing products.
15. If our products or services are not accepted by the market, we will not be able to sustain or expand our business.
16. We operate in the highly competitive health care industry, and we cannot be assured that we will be able to compete successfully.
17. New medical and technological developments may reduce the need for our products.
18. Product innovations are important in the industry in which we operate, and we face the risk of product obsolescence if we are unable to develop new products or gain regulatory approvals or certifications or if our competitors introduce new products.
19. We face risks related to environmental, social and governance matters.
20. Environmental, social and corporate governance issues, including those related to climate change and sustainability, may have an adverse effect on our business and damage our reputation.
21. If we do not retain our key personnel and attract and retain other highly skilled employees, our business could suffer.
22. Provisions of our governing documents and Delaware law may have anti-takeover effects.
23. Risks Relating to Government Regulation of Manufacture and Sale of Our Products and Services.
24. Legislative or regulatory reforms in the United States, Europe or other countries may make it more difficult and costly for us to obtain regulatory clearances, approvals or certifications for our products or to manufacture, market or distribute our products after clearance or approval is obtained.
25. Our products are subject to reporting requirements and recalls, even after receiving regulatory clearance, approval or certification, which could harm our reputation and business.
26. If our manufacturing operations fail to comply with applicable regulations, our manufacturing could be delayed or disrupted, our products could be subject to recall, and sales and profitability could suffer.
27. Our failure to comply with regulatory requirements or to receive regulatory clearance, approval or certification for our products or operations could adversely affect our business.
28. Development and marketing of our products are subject to strict governmental regulation by foreign regulatory agencies, and failure to receive, or delay in receiving, foreign qualifications or certifications could have a material adverse effect on our business.
29. Increased regulatory scrutiny of genetic testing may adversely affect our business through increased costs and risks associated with gaining marketing approvals or certifications and potential impact on demand for our genetic testing services.
30. If we fail to comply with applicable federal, state, local and foreign laboratory licensing requirements, we could lose the ability to perform our genetic tests or experience disruptions to our business.
31. Our HCT/P products are subject to extensive government regulation and our failure to comply with these requirements could cause our business to suffer.
32. Disruptions at the FDA and other government agencies or notified bodies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or approved or commercialized in a timely manner or at all, which could negatively impact our business.
33. Ethical, legal and social concerns related to the use of genetic information, sperm and egg selection services and stem cells could reduce demand for our service offerings.
34. The costs of complying with the requirements of federal, state and foreign laws pertaining to the privacy and security of personal information, including health related information and the potential liability associated with failure to do so could materially adversely affect our business.
35. Changes in legislation and government regulation of the health care industry both in the United States and internationally, as well as third-party payors' efforts to control the costs of health care could materially adversely affect our business.
36. Laws pertaining to health care fraud and abuse could materially adversely affect our business.

Read these in Item 1A · See the changes

1. Exchange rate fluctuations and foreign currency hedges could adversely affect our financial results.
2. We are vulnerable to interest rate risk with respect to our debt.Interest rates
3. Our indebtedness could adversely affect our financial health and prevent us from fulfilling our debt obligations.
4. Volatility in the securities markets, interest rates, and other factors could substantially increase our defined benefit plan costs.Interest rates

Read these in Item 1A · See the changes

1. Changes in tax laws, examinations by tax authorities, and changes in our geographic composition of income could adversely affect our financial results.

Read these in Item 1A · See the changes